Material Agreements

SPLASH BEVERAGE GROUP, INC. entered into Purchase Agreement with certain accredited investors valued at $1,850,000 (effective 2024-05-01).

“On May 1, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”). Pursuant to the Purchase Agreement, the Company sold the Purchasers: (i) senior convertible notes in the aggregate original principal amount of $1,850,000, (the “Notes”) convertible into up to 4,625,000 shares of common stock of the Company, par value $0.001 per share (“Common Stock”), subject to adjustments as provided in the Notes, (ii) 925,000 shares of Common Stock (the “Commitment Shares”), (ii) warrants to initially acquire up to an aggregate of 4,625,000 additional shares of Common Stock (the “Warrants”) at an exercise price of $0.85 per Warrant Share.”

Skyward Specialty Insurance Group, Inc. entered into Underwriting Agreement with Barclays Capital Inc., Keefe, Bruyette & Woods, Inc. and Jefferies LLC as representatives of the several underwriters valued at $36.50 per share (effective 2024-05-06).

“On May 6, 2024, Skyward Specialty Insurance Group, Inc., a Delaware corporation (the “Company”) and Westaim HIIG GP Inc. (the “Selling Stockholder”) entered in an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Keefe, Bruyette & Woods, Inc. and Jefferies LLC as representatives of the several underwriters named therein”

Bandwidth Inc. amended Credit Agreement with Bank of America, N.A., as administrative agent, swingline lender and letters of credit issuer (effective 2024-05-01).

“On May 1, 2024, Bandwidth Inc. (the “Company”) entered into an amendment (the “Credit Agreement Amendment”) to the credit agreement (as amended, the “Credit Agreement”) among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Bank of America, N.A., as administrative agent, swingline lender and letters of credit issuer, with BofA Securities, Inc. and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners.”

AmeriCann, Inc. terminated a lease with BASK, Inc. (effective 2024-05-03).

“☐ 1 ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT On July 26, 2019, the Company entered into a 15-Year Triple Net lease of Building 1 of the Massachusetts Cannabis Center with BASK, Inc. The lease commenced on September 1, 2019 and included a monthly base rent of $11,563.50 and a revenue participation fee equivalent to 15% of BASK’s gross revenues derived from products produced in the building.”

Loop Industries, Inc. entered into Agreement with Ester Industries Ltd. valued at USD $165 million (effective 2024-05-01).

“On May 1, 2024, Loop Industries, Inc. (the “Company” or “Loop”) entered into an agreement (the “Agreement”) by and between the Company and Ester Industries Ltd. (“Ester”).”

Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-05-06).

“In connection with the Private Placement, the Company entered into a registration rights agreement, dated May 6, 2024 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).”

Eledon Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors (the "Purchasers") valued at approximately $50 million (effective 2024-05-06).

“On May 6, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 13,110,484 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) at a price of $2.37 per share, and pre-funded warrants (the “Pre-Funded Warrants”) at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share.”

Driveitaway Holdings, Inc. entered into Credit Facility with an investor (the "Lender") valued at $2,000,000 line of credit (effective 2024-03-01).

“On March 1, 2024, DIA Leasing, LLC. (the "Borrower"), a direct wholly owned subsidiary of DriveitAway Holdings, Inc. ("DWAY"), closed a $2,000,000 line of credit facility (the "Credit Facility") with an investor (the "Lender").”

AMYRIS, INC. terminated DIP Credit Agreement with Euagore, LLC valued at DIP Credit Agreement was amended and restated as part of the Exit First Lien Facility, outstanding p (effective 2024-05-07).

“On the Effective Date, (x) the DIP Credit Agreement was amended and restated as part of the Exit First Lien Facility described below such that the outstanding principal amount due on the DIP Facility was reduced to $30 million and (y) $20 million of the DIP Facility Claims were converted into 100% of the New Common Stock of Reorganized Amyris.”

AMYRIS, INC. entered into Amended and Restated Loan Agreement (Exit First Lien Facility) with Euagore, LLC valued at up to $160 million aggregate principal amount (effective 2024-05-07).

“the Company, AB Technologies LLC, and Aprinnova, LLC (collectively, the “ Borrowers ”), and certain other subsidiaries of the Company (the “ Guarantors ”) entered into an Amended and Restated Loan Agreement (the “ Exit First Lien Facility ”), dated as of the Effective Date (as amended, restated, supplemented or otherwise modified from time to time), by and among the Borrowers, Guarantors, each lender from time to time party thereto (the “ Lenders ”) and Euagore, LLC, an affiliate of Foris Ventures LLC, in its capacity as administrative agent.”

Cooper-Standard Holdings Inc. amended Amendment No. 4 with certain lenders, Bank of America, N.A., as agent (effective 2024-05-06).

“(“CSA”), Cooper-Standard Automotive Canada Limited (the “Canadian Borrower”, and, together with CSA, the “Borrowers”) entered into Amendment No. 4 (the “Fourth Amendment”) to the Third Amended and Restated Loan Agreement (as amended, the “Credit Agreement”) with certain lenders, Bank of America, N.A., as agent (the “Agent”), and other parties thereto.”

Citi Trends Inc terminated Stockholder Protection Rights Agreement with Equiniti Trust Company, LLC (effective 2024-05-07).

“The Amendment terminated the Rights Agreement by accelerating the expiration time of the Company's preferred share purchase rights”

COMSCORE, INC. amended Amendment with Bank of America, N.A. valued at $40.0 million to $25.0 million (effective 2024-05-03).

“On May 3, 2024, comScore, Inc. (the "Company") entered into an amendment (the "Amendment") to its senior secured revolving credit agreement dated May 5, 2021 (the "Credit Agreement") among the Company, as borrower, the Company's subsidiaries from time to time party thereto, as guarantors, Bank of America, N.A., as administrative agent, and the lenders from time to time party thereto.”

MADRIGAL PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2024-05-07).

“The Sales Agreement replaces and supersedes the prior sales agreement, dated June 1, 2021 and amended on May 9, 2023, between the Company and Cowen and Company, LLC, an affiliate of TD Cowen (the “Prior Sales Agreement”), which was terminated effective upon the entry into the Sales Agreement.”

MADRIGAL PHARMACEUTICALS, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $300,000,000 (effective 2024-05-07).

“On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC, (“TD Cowen”), pursuant to which the Company may issue and sell through or to TD Cowen, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time having an aggregate sales price of up to $300,000,000 (the “ATM Offering”).”

ARVANA INC entered into Consulting Services Agreement with Social4orce, Inc. valued at $50,000 (effective 2024-04-29).

“On April 29, 2024, Arvana Inc. (“Company”) entered into a Consulting Services Agreement (“Agreement”) with Social4orce, Inc. (“Social4orce”) to assist in the development of its business. Social4orce offers expertise in generating a business development strategy, overseeing project management, interpreting market awareness, and accessing capital markets. The Company engaged Social4orce for an initial fee of $50,000”

ENTRAVISION COMMUNICATIONS CORP entered into Share Purchase Agreement with Adsmurai, S.L. and the other stockholders of Adsmurai valued at €15.0 million (approximately $16.2 million) (effective 2024-05-06).

“On May 6, 2024 (the "Effective Date"), Entravision Communications Corporation (the “Company”) entered into a Share Purchase Agreement (the “Purchase Agreement”), among Adsmurai, S.L. ("Adsmurai"), the Company and the other stockholders of Adsmurai (the “Buyers”).”

AGENUS INC entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $75 million (effective 2024-05-06).

“On May 6, 2024, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”)”

Piedmont Realty Trust, Inc. amended a credit facility valued at $200 million (effective 2024-05-06).

“On May 6, 2024, Piedmont Operating Partnership, LP, a subsidiary of Piedmont Office Realty Trust, Inc. (the “Registrant”), entered into amendments to the agreements governing its $200 million unsecured 2024 term loan, its $250 million unsecured 2018 term loan and its $600 million unsecured 2022 line of credit.”

LESAKA TECHNOLOGIES INC entered into Sale Agreement with Adumo (RF) Proprietary Limited valued at ZAR 1.59 billion ($85.9 million) (effective 2024-05-07).

“On May 7, 2024, Lesaka Technologies, Inc. ("Lesaka"), entered into a Sale and Purchase Agreement (the "Sale Agreement") with Lesaka Technologies Proprietary Limited ("Lesaka SA"), and the Sellers (as defined in the Sale Agreement).”

AI Financial Corp entered into Securities Purchase Agreement with two certain institutional investors valued at approximately $300,000 (effective 2024-05-01).

“On May 1, 2024, JanOne Inc. (the “ Company ” or “ our ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with two certain institutional investors (the “ Investors ”) for the sale by the Company in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “ Offering ”) of 79,782 units (the “ Units ”) of the Company’s securities, each Unit consisting of one share of our common stock, par value $0.001 per share (“ Common Stock ”), and one common stock purchase warrant for the purchase of an additional share of Common Stock (“ Warrants ”), at a purchase price of $3.775 per Unit.”

ALLETE INC entered into Agreement and Plan of Merger with Alloy Parent LLC and Alloy Merger Sub LLC valued at Merger consideration of $67.00 per share in cash, aggregate equity value approximately $3.9 billion (effective 2024-05-05).

“On May 5, 2024, ALLETE, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Alloy Parent LLC, a Delaware limited liability company (“Parent”), and Alloy Merger Sub LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Merger Sub”).”

GXO Logistics, Inc. entered into Indenture dated as of July 2, 2021, as supplemented by Second Supplemental Indenture dated May 6, 2024 with Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association) valued at $1.1 billion aggregate principal amount of senior notes ($600 million 2029 notes at 6.250% and $500 (effective 2024-05-06).

“On May 6, 2024, GXO Logistics, Inc. (“ GXO ”) completed its previously announced offering of $1.1 billion in aggregate principal amount of senior notes, consisting of $600 million in aggregate principal amount of notes due 2029 (the “ 2029 notes ”) and $500 million in aggregate principal amount of notes due 2034 (the “ 2034 notes ”, and together with the 2029 notes, the “ notes ”). The notes were issued pursuant to an indenture dated as of July 2, 2021 (the “ Base Indenture ”), as supplemented by the Second Supplemental Indenture dated as of May 6, 2024 (the “ Supplemental Indenture ”, and the Base Indenture as amended or supplemented by the Supplemental Indenture, the “ Indenture ”), in each case between GXO and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as trustee (the “ Trustee ”).”

Collective Audience, Inc. entered into Exercise Price Reset Agreement with certain accredited investors (effective 2024-04-26).

“On April 26, 2024 (the "Execution Date"), the Company entered into an Exercise Price Reset Agreement (the "Reset Agreement") with the Investors from the February Private Placement and December Private Placement pursuant to which, among other things, the Company agreed to reset the exercise price of the February Investor’s February Warrants from $5.00 per share of the Company’s common stock, par value $0.0001 (“Common Stock”), to $0.185 per share of Common Stock (the “Reset Exercise Price”) and to reset the December Investor’s December Warrants from an exercise price of $2.13 per share of Common Stock to the Reset Exercise Price.”

Nuburu, Inc. entered into Pre-Funded Warrant Purchase Program with strategic investors valued at $15 million (effective 2024-05-01).

“Nuburu, Inc. (the “Company”) entered into a Pre-Funded Warrant Purchase Program (the “Program”), effective as of May 1, 2024, with strategic investors, pursuant to which from time-to-time the Company may sell and the investors may acquire pre-funded warrants, up to a total purchase price to the Company equal to $15 million.”

Alight, Inc. / Delaware entered into Cooperation Agreement with Starboard Value and Opportunity Master Fund, Ltd. valued at Board appointments, standstill restrictions, expense reimbursement up to $625,000 (effective 2024-05-06).

“On May 6, 2024, Alight, Inc., a Delaware corporation (the “Company”), announced its entry into a cooperation agreement (the “Cooperation Agreement”) with Starboard Value and Opportunity Master Fund, Ltd. (together with its affiliates, “Starboard”).”

Next Technology Holding Inc. entered into Bitcoin Option Contract with Seller valued at Company may purchase up to 20,000 BTC at US$60,000 per BTC, locked for three years, with payment in (effective 2024-05-02).

“T Cover a 12-month period from a specified seller (“Seller”). As of the signing date of the Amendment, the Company had purchased”

Next Technology Holding Inc. amended Amendment Agreement to BTC Trading Contract with Seller valued at Consideration consists of 40,000,000 shares of common stock and 80,000,000 warrant shares; total BTC (effective 2024-05-02).

“On May 2, 2024, Next Technology Holding Inc. (formerly known as WeTrade Group Inc.), a Wyoming corporation (“Company”), entered into an Amendment Agreement(“Amendment”) to a BTC Trading Contract.”

Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at $2,000,000 (effective 2024-05-01).

“On May 1, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor.”

Angel Oak Mortgage REIT, Inc. amended Amended and Restated Management Agreement with Falcons I, LLC (effective 2024-05-01).

“On May 1, 2024, Angel Oak Mortgage REIT, Inc. (the "Company"), Angel Oak Mortgage Operating Partnership, LP, the Company's operating partnership, and Falcons I, LLC, the Company's external manager (the "Manager") amended and restated that certain Management Agreement dated as of June 21, 2021 to (i) clarify (a) the officers and employee(s) provided by the Manager that will be fully or partially dedicated to the Company and (b) the related full or partial reimbursements to the Manager for their salaries and other benefits, subject to the approval of the Compensation Committee, and (ii) update the names of various entities and make certain other minor updates.”

Canopy Growth Corp entered into Exchange and Subscription Agreement with MMCAP International Inc. SPC valued at approximately C$27.5 million aggregate principal amount of Supreme Debentures (effective 2024-05-02).

“On May 2, 2024, the Company entered into an Exchange and Subscription Agreement (the “ Exchange and Subscription Agreement ”) with MMCAP International Inc. SPC (the “ Investor ”) pursuant to which, among other things, the Investor agreed to deliver to the Company approximately C$27.5 million aggregate principal amount of Supreme Debentures maturing in September 2025 held by the Investor and pay the Company approximately US$50 million in exchange for the Company issuing to the Investor (i) a new senior unsecured convertible debenture of the Company with an aggregate principal amount of C$96,358,375”

Canopy Growth Corp entered into Second Amended and Restated Limited Liability Company Agreement with Canopy USA, LLC and its members, 11065520 Canada Inc. and the Huneeus 2017 Irrevocable Trust (effective 2024-04-30).

“On April 30, 2024, Canopy USA and its members, 11065520 Canada Inc. and the Huneeus 2017 Irrevocable Trust, entered into a Second Amended and Restated Limited Liability Company Agreement (the “ Second A&R LLC Agreement ”) which amended and restated the prior amended and restated limited liability company agreement of Canopy USA”

Gossamer Bio, Inc. entered into Chiesi Collaboration Agreement with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, Chiesi) valued at Upfront payment of $160 million, plus up to $146 million in regulatory milestones and $180 million i (effective 2024-05-03).

“On May 3, 2024, Gossamer Bio, Inc. (“Gossamer” or the “Company”), GB002, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“GB002”), and Gossamer Bio 002 Ltd., a corporation organized and existing under the laws of Ireland and indirect wholly-owned subsidiary of the Company, entered into a global collaboration and license agreement (the “Chiesi Collaboration Agreement”) with Chiesi Farmaceutici S.p.A and Chiesi USA, Inc. (collectively, “Chiesi”). The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds (“Licensed Products”) in the US (“US Territory”) and the rest of the world (“ROW Territory”), for therapeutic, prophylactic and diagnostic uses in humans and animals, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and other indications, as may be permitted under the Chiesi Co”

HF Foods Group Inc. entered into Assignment and Assumption of Lease Agreement with 273 Fifth Avenue, L.L.C. (effective 2024-04-30).

“On April 30, 2024, 273 Fifth Avenue, L.L.C. (“Assignee”), a Delaware limited liability company and wholly owned subsidiary of the Company assumed the lease of the premises at 275 Fifth Avenue, New York, New York, dated as of July 2, 2018 (the "Lease"), as amended by that certain Amendment to Lease, dated as of January 21, 2021, (the “Amendment to Lease”), between 825 Broadway Realty, LLC, Samayabeneli RE LLC, AS 2 East 30, LLC, 273 Yoco LLC, and UBA 2 East 30, LLC (collectively, the “Landlord”), and Anheart Inc., a New York corporation and a former subsidiary of the Company (the “Assignor”), pursuant to an Assignment and Assumption of Lease Agreement (the “Assignment”), dated as of August 16, 2022 and effective between Assignor and Assignee as of April 30, 2024 (the “Effective Date”), when Landlord consent was obtained.”

Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).

“On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).”

Braemar Hotels & Resorts Inc. entered into Agreement of Purchase and Sale with JRK Torrey Pines Hotel Owner LLC valued at $165 million (effective 2024-05-06).

“On May 6, 2024 (the “Effective Date”), CHH Torrey Pines Hotel Partners, LP and CHH Torrey Pines Tenant Corp. (together, “Seller”), indirect subsidiaries of Braemar Hotels & Resorts Inc. (the “Company”), entered into an Agreement of Purchase and Sale (the “Agreement”) with JRK Torrey Pines Hotel Owner LLC (“Purchaser”), for the sale of the Hilton La Jolla Torrey Pines hotel (“Hilton Torrey Pines”) for $165 million in cash”

Arch Therapeutics, Inc. amended Amendment No. 2 to the Fourth Notes with holders of the Company's outstanding Unsecured Convertible Promissory Notes valued at Under the Amendments to the Notes, the Notes were amended to extend the date of the completion of an (effective 2024-04-30).

“On April 30, 2024, the Company also entered into an amendment (" Amendment No. 2 to the Fourth Notes " and, together with Amendment No. 16 to the First Notes, Amendment No. 16 to the Second Notes and Amendment No. 11 to the Third Notes, the " Amendments to the Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on March 15, 2024, issued in connection with a private placement financing the Company completed on March 12, 2024 (as amended, the " Fourth Notes " and, together with the First Notes, Second Notes, and Third Notes, the " Notes ").”

Arch Therapeutics, Inc. amended Amendment No. 11 to the Third Notes with holders of the Company's outstanding Unsecured Convertible Promissory Notes valued at Under the Amendments to the Notes, the Notes were amended to extend the date of the completion of an (effective 2024-04-30).

“On April 30, 2024, the Company also entered into an amendment (" Amendment No. 11 to the Third Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024 and March 15, 2024 (as amended, the " Third Notes "), issued in connection with a private placement financing the Company completed on May 15, 2023.”

Arch Therapeutics, Inc. amended Amendment No. 16 to the Second Notes with holders of the Company's outstanding Unsecured Convertible Promissory Notes valued at Under the Amendments to the Notes, the Notes were amended to extend the date of the completion of an (effective 2024-04-30).

“On April 30, 2024, the Company also entered into an amendment (" Amendment No. 16 to the Second Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on February 14, 2023, March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024 and March 15, 2024 (as amended, the " Second Notes "), issued in connection with a private placement financing the Company completed on January 18, 2023.”

Arch Therapeutics, Inc. amended Amendment No. 4 to the Bridge Registration Rights Agreement with certain institutional and accredited individual investors valued at Amended to redefine 'Uplist' as the public offering of the Company's Common Stock pursuant to a regi (effective 2024-05-01).

“On May 1, 2024, the Company entered into an amendment (" Amendment No. 4 to the Bridge Registration Rights Agreement ") to that certain Registration Rights Agreement, dated as of July 7, 2023, as amended on August 30, 2023, and as subsequently amended on November 8, 2023 and November 21, 2023, by and among the Company and certain institutional and accredited individual investors (as amended the " Bridge Registration Rights Agreement ") in connection with a private placement offering of pre-funded warrants to purchase shares of Common Stock, common warrants to purchase shares of Common Stock, and shares of Common Stock. Under Amendment No. 4 to the Bridge Registration Rights Agreement, the Bridge Registration Rights Agreement was amended to redefine "Uplist" as the public offering of the Company's Common Stock pursuant to a registration statement on Form S-1 that results in the listing of the Company's Common Stock on any securities exchange registered with the SEC as a "national securi”

Arch Therapeutics, Inc. amended Amendment No. 1 to the Third A&R Registration Rights Agreement with certain institutional and accredited individual investors valued at Amended to redefine 'Uplist Transaction' as the listing of the Company's common stock on any securit (effective 2024-04-30).

“On April 30, 2024, Arch Therapeutics, Inc. (the " Company ") entered into an amendment (" Amendment No. 1 to the Third A&R Registration Rights Agreement ") to that certain Third Amended and Restated Registration Rights Agreement, dated as of March 12, 2024, by and among us and certain institutional and accredited individual investors, as amended (the " A&R Registration Rights Agreement "). Under Amendment No. 1 to the Third A&R Registration Rights Agreement, the A&R Registration Rights Agreement was amended to redefine "Uplist Transaction" as the listing of the Company's common stock, par value $0.001 (" Common Stock "), on any securities exchange registered with the U.S. Securities and Exchange Commission (" SEC ") as a "national securities exchange" under Section 6 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ").”

Premier Air Charter Holdings Inc. amended Amendment No. 2 to the Agreement and Plan of Merger with TIPP Aviation, LLC (effective 2024-05-01).

“On May 1, 2024, the registrant ("Altair") executed Amendment No. 2 to the Agreement and Plan of Merger (“Amendment 2 to Merger Agreement”) among Premier Air Charter, Inc. (“Premier”), Premier Air Charter Merger Sub, Inc. (“Merger Sub”), and TIPP Aviation, LLC, the sole shareholder of Premier.”

Contango Silver & Gold Inc. entered into Arrangement Agreement with HighGold Mining Inc. valued at total HighGold equity value of approximately $37 million (effective 2024-05-01).

“On May 1, 2024, Contango ORE, Inc. (“Contango” or the “Company”) entered into a definitive arrangement agreement (the “Arrangement Agreement”), by and among the Company, Contango Mining Canada Inc., a corporation organized under the laws of British Columbia and a wholly owned subsidiary of the Company, and HighGold Mining Inc., a corporation existing under the laws of the Province of British Columbia (“HighGold”), pursuant to which the Company intends to acquire 100% of the outstanding equity interests of HighGold (the “HighGold Acquisition”).”

T2 Biosystems, Inc. entered into Consent and Amendment No. 11 to Term Loan Agreement with Administrative Agent and Lenders under the Loan Agreement (effective 2024-05-03).

“On May 3, 2024, the Company entered into the Consent and Amendment No. 11 to Term Loan Agreement (“ Consent No. 11 ”) to the Loan Agreement. Consent No. 11 provides for, among other things, (i) the consent of the Administrative Agent and the Lenders (who constitute all of the lenders under the Loan Agreement) to the Exchange and (ii) an amendment to the “Change of Control” definition”

T2 Biosystems, Inc. entered into Securities Purchase Agreement with CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. valued at $15.0 million (effective 2024-05-03).

“On May 3, 2024, the Company entered into a Securities Purchase Agreement (the “ SPA ”) with CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (collectively in such capacity, the “ Lenders ” or the “ Purchasers ”) pursuant to which the Company issued to the Lenders in a private placement offering 4,748,335 shares (the “ Shares ”) of the Company’s common stock in exchange for the Lenders surrendering for cancellation $15.0 million of outstanding loans”

Sweetgreen, Inc. amended Letter Agreement with Welcome to the Dairy, LLC valued at Landlord receives 100% of Company's profits under Sublease in excess of amounts payable under Lease; (effective 2024-04-30).

“In connection with the Landlord’s consent to the Sublease Agreement, the Company and the Landlord entered into a letter agreement, dated as of April 30, 2024, modifying the terms of the Lease (the “ Letter Agreement ”).”

Sweetgreen, Inc. entered into Sublease Agreement with FPM Development, LLC valued at Monthly base rent ranging from $399,844.25 to $491,757.99; annual base rent from $4,398,286.75 to $5 (effective 2024-04-30).

“On April 30, 2024, Sweetgreen, Inc. (the “ Company ”) entered into a sublease agreement (the “ Sublease Agreement ”) with FPM Development, LLC, a Wyoming limited liability company (the “ Subtenant ”), pursuant to which the Company will sublease approximately 57,681 square feet of space (the “ Phase I Premises ”) and approximately 36,400 square feet of space (the “ Phase II Premises ” and together with the Phase I Premises, the “ Premises ”) located at 3101 Exposition Boulevard, Los Angeles, California 90018.”

Axe Compute Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $3,696,000 (effective 2024-05-03).

“On May 3, 2024, Predictive Oncology Inc., a Delaware corporation, (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock, par value $0.01 per share, from time to time, through an “at the market offering” program pursuant to which Wainwright will act as sales agent.”

Appgate, Inc. amended A&R Note Issuance Agreement with Magnetar Financial LLC (effective 2024-05-02).

“(“ ES Colombia ” and, collectively with the Domestic Subsidiary Guarantors, Appgate and ES Japan, the “ Note Guarantors ”), Magnetar Financial LLC (collectively with its affiliates, “ Magnetar ”), as representative of the lenders, (the “ Lenders ”) party to that certain A&R Note Purchase Agreement, dated June 9, 2023, by and among Legacy Appgate and the Lenders (the “ A&R Note Purchase Agreement ”), and U.S.”

Cardinal Ethanol LLC amended First Amendment of Second Amended and Restated Construction Loan Agreement with First National Bank of Omaha (effective 2024-04-30).

“On April 30, 2024, Cardinal Ethanol, LLC, and its wholly owned subsidiary, Cardinal Colwich, LLC (collectively the “Company”), executed a First Amendment of Second Amended and Restated Construction Loan Agreement, which amends the Second Amended and Restated Construction Loan Agreement dated January 31, 2024, with First National Bank of Omaha (the "Amendment").”